Brain changes occurring in aging can be indexed by biomarkers. We used cluster analysis
to identify subgroups of cognitively unimpaired individuals (n= 99, 64–93 years) with …

Background: Changes in cerebrospinal fluid, neuroimaging, and cognitive functions have
been used as diagnostic biomarkers of Alzheimer's disease (AD). This study aimed to …

The independent effects of different brain pathologies on age-dependent cognitive decline
are unclear. We examined this in 300 cognitively unimpaired elderly individuals from the …

Detecting deviations from healthy brain aging is critical for identifying individuals at greatest
risk for developing dementia. Yet because there is substantial overlap in patterns of …

We investigated whether amyloid-β (Aβ) and tau affected cognition in cognitively normal
(CN) individuals, and whether norms for neuropsychological tests based on biomarker …

Typical cognitive aging is often defined as aging free of dementia, and yet it does not seem
to exclude dementia-related pathology. The most common type of dementia is Alzheimer's …

Plasma biomarkers are promising prognostic tools in individuals with subjective cognitive
decline (SCD). We aimed to investigate the relationships of baseline plasma amyloid beta …

Background: Identifying older adults at risk of cognitive decline represents a challenge as
Alzheimer's disease (AD) modifying therapies move toward preclinical stages. Objective: To …

Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) need to be characterized
in cognitively unimpaired (CU) elderly individuals. We therefore tested if plasma …

Objectives To investigate the ability of cerebrospinal fluid (CSF) and plasma measures to
discriminate early-stage Alzheimer disease (AD)(defined by clinical criteria and …